Method for exploring influence of hepatic hydatid on hepatitis
Through systematic case screening, data collection and analysis methods, the impact of hydatum on hepatitis was explored, and the problem of lack of systematic inquiry methods in the existing technology was solved, and scientific basis was provided to provide support for clinical application and scientific research.
Patent Information
- Application Number
- CN202510105707.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-23
- Publication Date
- 2025-05-13
AI Technical Summary
The existing technology lacks systematic research methods and data support, making it difficult to comprehensively evaluate the long-term impact of hepatic hydatum on hepatitis, especially the interaction mechanism and comprehensive impact of the two diseases coexist.
A method including case screening, data collection, data analysis, determination of research subjects and follow-up studies was adopted. By establishing a database and conducting statistical analysis, the differences in various indicators between cases of hepatic hydatum combined with hepatitis and cases of pure viral hepatitis were compared to the impact of hepatitis.
It has achieved scientific and systematic exploration of the impact of hydatum on hepatitis, providing a strong basis for clinical diagnosis, treatment and prevention, and has important clinical application value and scientific research significance.
Smart Images
Figure CN119993537A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical research, and specifically relates to a method for exploring the influence of echinococcosis on hepatitis. Background Art
[0002] Hepatic echinococcosis and viral hepatitis are two common liver diseases, caused by parasites and viruses, respectively, which have serious impacts on the health of patients. Hepatic echinococcosis is mainly prevalent in pastoral areas and is caused by echinococcosis parasitizing the liver. Its lesions can lead to liver fibrosis and liver function damage. Viral hepatitis is caused by infection with a variety of hepatitis viruses (such as type A, type B, type C, etc.), and is characterized by strong infectivity, long course of disease, and easy chronicity. In clinical practice, hepatic echinococcosis and hepatitis may coexist, and the interaction between the two may aggravate liver damage and affect disease progression and treatment effects.
[0003] However, the current research on the specific effects of echinococcosis on hepatitis is insufficient, lacking systematic research methods and data support. Traditional diagnostic and research methods mainly focus on the diagnosis and treatment of a single disease, and lack in-depth discussion of the interaction mechanism and combined impact of the two diseases when they coexist. In addition, most existing studies are case reports or small-scale studies, lacking large-scale, systematic follow-up studies, making it difficult to fully evaluate the long-term effects of echinococcosis on hepatitis. Summary of the invention
[0004] The present invention aims to provide a method for exploring the influence of echinococcosis on hepatitis, to provide a scientific and systematic exploration method, to comprehensively and deeply explore the influence of echinococcosis on hepatitis, and to provide a strong basis for clinical diagnosis, treatment and prevention.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows: A method for exploring the effect of hepatic echinococcosis on hepatitis, characterized by comprising the following steps: S1. Case screening: cases of echinococcosis and viral hepatitis were selected from hospitals in areas with high incidence of echinococcosis; S2. Data collection: Collect detailed medical history data of the patients screened in step S1, including basic information of the patients, laboratory test results, imaging results, and pathological results; S3, data analysis: statistically analyze the data collected in step S2, establish a database, compare the differences in various indicators between cases of hepatic echinococcosis combined with hepatitis and cases of simple viral hepatitis, and preliminarily analyze the impact of hepatic echinococcosis on hepatitis; S4. Determine the research subjects: patients diagnosed with viral hepatitis and confirmed with hydatid infection by imaging and pathological examinations were selected as the research subjects, and patients diagnosed with viral hepatitis but not infected with hydatid infection during the same period were selected as the control group for matching; S5. Follow-up study: Establish a follow-up cohort and regularly follow up the research subjects and control group patients in step S4; S6. Follow-up data analysis: The follow-up data of the research subjects and the control group patients in step S5 were collected and the co-infection rate of echinococcosis and viral hepatitis was calculated using the direct standardization method. Combined with the national big data on hepatitis prevalence, the impact of echinococcosis on hepatitis was analyzed.
[0006] Preferably, in step S1, cases of echinococcosis are selected from hospitals in areas with a high incidence of echinococcosis and screened according to the diagnostic criteria for echinococcosis, and cases with combined hepatitis are screened according to the diagnostic criteria for viral hepatitis.
[0007] Preferably, in step S2, the basic information of the case patient includes sociodemographic information, medical history and lifestyle; the laboratory test results include routine blood tests, liver function, coagulation function, liver fibrosis indicators and infectious disease indicators; the imaging test results include liver B-ultrasound elastic imaging and liver CT examination results; the pathological results are the postoperative liver pathological section results of the case patient.
[0008] Preferably, the sociodemographic information includes gender, age, ethnicity, job, address, and contact information.
[0009] Preferably, the past medical history includes history of infectious diseases, disease history, surgical history, and family medical history.
[0010] Preferably, the lifestyle includes smoking history, drinking history, and contact with cattle and sheep.
[0011] Preferably, in step S4, the pairing criteria for the research subjects and the control group patients are: age difference of not less than 5 years, viral hepatitis disease duration difference of less than 5 years, no serious underlying disease, consistent hepatitis B two-to-one, hepatitis B NDA, hepatitis C test results, and consistent family history of tumors.
[0012] Preferably, in step S5, the follow-up methods are telephone follow-up and hospital follow-up, the telephone follow-up content is the basic information of the research subjects and the control group patients, and the hospital follow-up content is: one or more of laboratory examinations, imaging examinations and immune index tests for the research subjects and the control group patients.
[0013] Preferably, the basic information of the research subjects and the control group patients includes one or more of occupation, animal contact history, smoking history, drinking history, whether they have infectious diseases, whether they have newly contracted other chronic diseases, long-term medication, surgical history, outcome (improved, cured, not cured, other), previous treatment and outcome of hepatitis B (hepatitis C), and previous treatment and outcome of liver cancer.
[0014] Preferably, the laboratory examination includes one or more of blood routine, liver function test, liver fibrosis test, and virus serum test; the imaging examination is liver B-ultrasound elastic imaging; the immune index detection is the detection of CD4 + 、CD8 + , one or more of IL-2, IFN-γ, IL-4, IL-10, IL-17, IL-12, IL-6, and TGF-β.
[0015] Compared with the prior art, the present invention has the following advantages and technical effects: The method for exploring the influence of hydatid cyst on hepatitis disclosed in the present invention can effectively explore the influence of hydatid cyst on hepatitis, provide scientific basis and technical support for the diagnosis, treatment and prevention of related diseases, and has important clinical application value and scientific research significance.
[0016] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is two-dimensional shear wave imaging according to embodiment 1 of the present invention, wherein: Figure 1 A in the figure is the result of the group with co-occurrence of hepatitis and hepatic cystic echinococcosis. Figure 1 B in the figure represents the simple hepatitis group. DETAILED DESCRIPTION
[0018] The technical solution of the present invention is further illustrated by the following embodiments.
[0019] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.
[0020] In the present invention, unless otherwise specified, other test materials and instruments and equipment are conventional test materials in the art and can be purchased through commercial channels.
[0021] Example 1 S1. Case screening: Five division-level and municipal hospitals in areas with high incidence of hepatic echinococcosis were selected within the Xinjiang Production and Construction Corps. Cases of hepatic cystic echinococcosis and hepatitis B in the past 10 years were selected. Among them, cases of hepatic cystic echinococcosis were selected and screened according to the diagnostic criteria of hepatitis B. At the same time, according to the diagnostic criteria of hepatitis B, cases of hepatitis B and hepatic cystic echinococcosis co-infection group were screened, and hepatitis B cases were selected and screened according to the diagnostic criteria of hepatitis B; S2. Data collection: Collect detailed medical history data of the case patients screened in step S1, including (1) basic information of the case patients: sociodemographic information (gender, age, ethnicity, work, address, contact information), medical history (history of infectious diseases, medical history, surgical history, family medical history) and lifestyle (history of smoking, history of drinking, contact with cattle and sheep); (2) laboratory test results: blood routine, liver function, coagulation function, liver fibrosis indicators and infectious disease indicators; (3) imaging test results: liver B-ultrasound elastic imaging and liver CT examination results; (4) pathological results: postoperative liver pathological section results of the case patients; S3, data analysis: statistically analyze the data collected in step S2, establish a database, compare the differences in various indicators between cases of hepatitis B and hepatic cystic echinococcosis and hepatitis B cases, and preliminarily analyze the impact of hepatic echinococcosis on hepatitis; S4. Determine the research subjects: patients diagnosed with viral hepatitis and confirmed with hydatid infection by imaging examination and pathological examination were selected as the research subjects, and patients diagnosed with viral hepatitis but not infected with hydatid infection during the same period were selected as the control group for matching. The matching criteria between the research subjects and the control group patients were: age difference of not less than 5 years, viral hepatitis duration difference of less than 5 years, no serious underlying diseases, consistent results of hepatitis B two-to-one, hepatitis B NDA, hepatitis C test, and consistent family history of tumors, as shown in Table 1.
[0022] Table 1 Pairing information of the research subjects and the control group patients
[0023] S5. Follow-up study: establish a follow-up cohort, and regularly follow up the research subjects and control group patients in step S4, wherein the follow-up methods include telephone follow-up and hospital follow-up, and the telephone follow-up content includes occupation, animal contact history, smoking history, drinking history, whether there is infectious disease, whether there is new other chronic disease, long-term medication, surgical history, prognosis (improved, cured, not cured, other), previous treatment and prognosis of hepatitis B (hepatitis C), previous treatment and prognosis of liver cancer, and the hospital follow-up content includes: laboratory examination of the research subjects and control group patients (liver function: ALT, AST, ALP, TBil, ALB, liver fibrosis test: serum hyaluronic acid HA, serum laminin (LN), serum type III procollagen (PCⅢ), serum type IV procollagen (CⅣ) and immune index detection (IL-6, IL-10, TGF-β in blood); S6. Follow-up data analysis: The follow-up data of the research subjects and the control group patients in step S5 were collected and the co-infection rate of echinococcosis and viral hepatitis was calculated using the direct standardization method. Combined with the national big data on hepatitis prevalence, the impact of echinococcosis on hepatitis was analyzed.
[0024] The impact of hydatid cyst on hepatitis is analyzed through the following data: Table 2 Immune index test results
[0025] As shown in Table 1, the IL-6 level in the simple hepatitis B group was significantly higher than that in the hepatitis B and hepatic cystic echinococcosis co-infection group, indicating that echinococcosis inhibits the high expression of IL-6 through immune regulation and reduces the inflammatory response. The TGF-β level in the co-infection group was higher, indicating that echinococcosis has an inhibitory effect on liver fibrosis. In summary, according to the serum levels of IL-6, IL-10 and TGF-β, the co-infection of hepatic cystic echinococcosis slows down the progression of hepatitis B by inhibiting proinflammatory factors and increasing immunomodulatory factors, thereby playing a certain inhibitory role in the development of hepatitis.
[0026] Table 3 Liver fibrosis test
[0027] As shown in Table 3, some liver fibrosis-related indicators showed significant differences between the hepatitis B and hepatitis B co-infection group and the hepatitis B simple group. The serum hyaluronic acid (HA), type III procollagen (PCⅢ) and type IV procollagen (CⅣ) levels in the co-infection group were significantly lower than those in the hepatitis simple group (P values were 0.048, 0.049 and 0.039, respectively), that is, hepatic cystic echinococcosis inhibited the activation of hepatic stellate cells, reduced the synthesis of extracellular matrix and collagen, and thus slowed down the process of liver fibrosis. At the same time, although the level of laminin (LN) in the co-infection group was slightly lower than that in the hepatitis simple group, the difference was not statistically significant (P=0.371), reflecting its time dependence or different mechanism of action in the early stage of fibrosis or repair process. The overall results show that hepatic cystic echinococcosis has a certain inhibitory effect on the process of liver fibrosis through immune regulation mechanism, which provides a new perspective for studying the effect of co-morbidity on liver fibrosis.
[0028] Two-dimensional shear wave imaging (SWE) is a non-invasive technique used to assess liver stiffness (i.e., the degree of liver fibrosis), which is closely related to the degree of liver fibrosis. The results are shown in Table 4.
[0029] Table 4 Results of two-dimensional shear wave imaging indicators
[0030] As shown in Table 4, the liver stiffness of the simple hepatitis B group was significantly higher than that of the hepatitis B and hepatic cystic echinococcosis co-infection group, indicating that the degree of liver fibrosis in the simple hepatitis B group was higher. The liver stiffness of the hepatitis B and hepatic cystic echinococcosis co-infection group was lower than that of the simple hepatitis B group, further indicating the inhibitory effect of echinococcosis on liver fibrosis.
[0031] Depend on Figure 1It can be seen that the degree of liver fibrosis in the group with hepatitis B and hepatic cystic echinococcosis is lighter than that in patients with simple hepatitis.
[0032] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for exploring the effect of hydatid cyst on hepatitis, characterized in that: The following steps are involved: S1. Case screening: cases of echinococcosis and viral hepatitis were selected from hospitals in areas with high incidence of echinococcosis; S2. Data collection: Collect detailed medical history data of the patients screened in step S1, including basic information of the patients, laboratory test results, imaging results, and pathological results; S3, data analysis: statistically analyze the data collected in step S2, establish a database, compare the differences in various indicators between cases of hepatic echinococcosis combined with hepatitis and cases of simple viral hepatitis, and preliminarily analyze the impact of hepatic echinococcosis on hepatitis; S4. Determine the research subjects: patients diagnosed with viral hepatitis and confirmed with hydatid infection by imaging and pathological examinations were selected as the research subjects, and patients diagnosed with viral hepatitis but not infected with hydatid infection during the same period were selected as the control group for matching; S5. Follow-up study: Establish a follow-up cohort and regularly follow up the research subjects and control group patients in step S4; S6. Follow-up data analysis: The follow-up data of the research subjects and the control group patients in step S5 were collected and the co-infection rate of echinococcosis and viral hepatitis was calculated using the direct standardization method. Combined with the national big data on hepatitis prevalence, the impact of echinococcosis on hepatitis was analyzed.
2. A method for investigating the effect of hydatid cyst on hepatitis according to claim 1, characterized in that: In step S1, cases of echinococcosis are selected from hospitals in areas with a high incidence of echinococcosis and screened according to the diagnostic criteria for echinococcosis. At the same time, cases with combined hepatitis are screened according to the diagnostic criteria for viral hepatitis.
3. A method for investigating the effect of hydatid cyst on hepatitis according to claim 1, characterized in that: In step S2, the basic information of the case patient includes sociodemographic information, medical history and lifestyle; the laboratory test results include blood routine, liver function, coagulation function, liver fibrosis indicators and infectious disease indicators; the imaging test results include liver B-ultrasound elastic imaging and liver CT examination results; the pathological results are the postoperative liver pathological section results of the case patient.
4. A method for investigating the effect of hydatid cyst on hepatitis according to claim 1, characterized in that: In step S5, the follow-up methods are telephone follow-up and hospital follow-up. The content of the telephone follow-up is the basic information of the research subjects and the control group patients. The content of the hospital follow-up is: one or more of laboratory examinations, imaging examinations and immune index tests for the research subjects and the control group patients.
5. A method for investigating the effect of hydatid cyst on hepatitis according to claim 4, characterized in that: The laboratory examination includes one or more of blood routine, liver function, liver fibrosis test, and virus serum test; the imaging examination is liver B-ultrasound elastic imaging; the immune index detection is the detection of CD4 + 、CD8 + , one or more of IL-2, IFN-γ, IL-4, IL-10, IL-17, IL-12, IL-6, and TGF-β.